SCHEMBL2583910

SCHEMBL2583910

CCOc1ccc(Br)c(OCOC)c1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCOA1 Q15788 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LMNA P02545 1/20 0.38
MAPT P10636 3/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
LARS1 Q9P2J5 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TUBB1 Q9H4B7 2/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36
TUBB3 Q13509 1/20 0.36
TUBB2A Q13885 1/20 0.36
TUBB8 Q3ZCM7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14736781 0.88 TUBB1 (0.40) MAPK1LMNAMAPTGAASMN1; SMN2
SCHEMBL6899392 0.82 MAPT (0.40) MAPK1LMNAMAPTKDM4ELARS1
SCHEMBL28295578 0.80 LARS1 (0.42) HSD17B10LMNAMAPTKDM4ELARS1
SCHEMBL2591433 0.80 ALOX5AP (0.34) MAPTTUBB1HPGD
SCHEMBL31096290 0.77 MAPT (0.43) NCOA1NCOA3MAPK1HSD17B10LMNA
SCHEMBL21823652 0.77 MAPT (0.43) NCOA1NCOA3MAPK1HSD17B10LMNA
SCHEMBL16979115 0.76 ALOX5AP (0.44) NCOA1NCOA3MAPK1HSD17B10LMNA
SCHEMBL2589018 0.76 BACE1 (0.35) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL16067896 0.75 NCOA1 (0.47) NCOA1NCOA3MAPK1HSD17B10LMNA
SCHEMBL2591598 0.75 ERN1 (0.47) MAPK1HSD17B10LMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A NCOA1 2219/4885NCOA3 988/4885MAPK1 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.